Test
CAS: 53-85-0 Molecular Formula: C12H12Cl2N2O4 Molecular Weight (g/mol): 319.138 MDL Number: MFCD00036785 InChI Key: XHSQDZXAVJRBMX-DDHJBXDOSA-N Synonym: 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole,dichlororibofuranosylbenzimidazole,drb,5,6-dichlorobenzimidazole riboside,5,6-dichlorobenzimidazole 1-beta-d-ribofuranoside,5,6-dichloro-1-.beta.-d-ribofuranosylbenzimidazole,benzimidazole, 5,6-dichloro-1-beta-d-ribofuranosyl,5,6-dichloro-1-beta-d-ribofuranosyl-1h-benzimidazole,2r,3r,4s,5r-2-5,6-dichloro-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol,2r,3r,4s,5r-2-5,6-dichloro-1h-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol PubChem CID: 5894 IUPAC Name: (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol SMILES: C1=C2C(=CC(=C1Cl)Cl)N(C=N2)C3C(C(C(O3)CO)O)O
PubChem CID | 5894 |
---|---|
CAS | 53-85-0 |
Molecular Weight (g/mol) | 319.138 |
MDL Number | MFCD00036785 |
SMILES | C1=C2C(=CC(=C1Cl)Cl)N(C=N2)C3C(C(C(O3)CO)O)O |
Synonym | 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole,dichlororibofuranosylbenzimidazole,drb,5,6-dichlorobenzimidazole riboside,5,6-dichlorobenzimidazole 1-beta-d-ribofuranoside,5,6-dichloro-1-.beta.-d-ribofuranosylbenzimidazole,benzimidazole, 5,6-dichloro-1-beta-d-ribofuranosyl,5,6-dichloro-1-beta-d-ribofuranosyl-1h-benzimidazole,2r,3r,4s,5r-2-5,6-dichloro-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol,2r,3r,4s,5r-2-5,6-dichloro-1h-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol |
IUPAC Name | (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
InChI Key | XHSQDZXAVJRBMX-DDHJBXDOSA-N |
Molecular Formula | C12H12Cl2N2O4 |
CAS: 53-85-0 Molecular Formula: C12H12Cl2N2O4 Molecular Weight (g/mol): 319.138 MDL Number: MFCD00036785 InChI Key: XHSQDZXAVJRBMX-DDHJBXDOSA-N Synonym: 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole,dichlororibofuranosylbenzimidazole,drb,5,6-dichlorobenzimidazole riboside,5,6-dichlorobenzimidazole 1-beta-d-ribofuranoside,5,6-dichloro-1-.beta.-d-ribofuranosylbenzimidazole,benzimidazole, 5,6-dichloro-1-beta-d-ribofuranosyl,5,6-dichloro-1-beta-d-ribofuranosyl-1h-benzimidazole,2r,3r,4s,5r-2-5,6-dichloro-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol,2r,3r,4s,5r-2-5,6-dichloro-1h-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol PubChem CID: 5894 IUPAC Name: (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol SMILES: C1=C2C(=CC(=C1Cl)Cl)N(C=N2)C3C(C(C(O3)CO)O)O
PubChem CID | 5894 |
---|---|
CAS | 53-85-0 |
Molecular Weight (g/mol) | 319.138 |
MDL Number | MFCD00036785 |
SMILES | C1=C2C(=CC(=C1Cl)Cl)N(C=N2)C3C(C(C(O3)CO)O)O |
Synonym | 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole,dichlororibofuranosylbenzimidazole,drb,5,6-dichlorobenzimidazole riboside,5,6-dichlorobenzimidazole 1-beta-d-ribofuranoside,5,6-dichloro-1-.beta.-d-ribofuranosylbenzimidazole,benzimidazole, 5,6-dichloro-1-beta-d-ribofuranosyl,5,6-dichloro-1-beta-d-ribofuranosyl-1h-benzimidazole,2r,3r,4s,5r-2-5,6-dichloro-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol,2r,3r,4s,5r-2-5,6-dichloro-1h-1,3-benzodiazol-1-yl-5-hydroxymethyl oxolane-3,4-diol |
IUPAC Name | (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
InChI Key | XHSQDZXAVJRBMX-DDHJBXDOSA-N |
Molecular Formula | C12H12Cl2N2O4 |
5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a transcriptional elongation inhibitor.Cyclin-dependent kinases (CDKs) belong to a family of protein kinases involved in regulating the cell cycle, transcription, mRNA processing, and the differentiation of nerve cells.[1] They are expressed in all known eukaryotes. With cyclin, CDK shows kinase activity. CDKs are serine-threonine kinases [1].DRB inhibited the activity of several carboxyl-terminal domain (CTD) kinases including casein kinase II, Cdk7, Cdk8, and Cdk9 with the IC50 of 4-10 μM, ~20 μM, ~20 μM, and 3 μM) [2-5]. In HeLa cells, DRB (75 μM) inhibited 60-75% of nuclear heterogeneous RNA (hnRNA) synthesis. DRB (75 μM) reduced the appearance of labeled cytoplasmic poly(A)-containing messenger RNA (mRNA) by approximately 95%. DRB inhibited the initiation of hnRNA chains, but did not directly interfere with labeling of poly(A) [6]. Other sizes are also available. Please inqury us for quote.
DRB is a potent and specific inhibitor of casein kinase II (CKII, IC50~6 µM). It has been used to inhibit RNA polymerase II mediated-transcription which may be dependent on CKII and its interaction with ATF-1. Alternative name: DRB, 5,6-Dichlorobenzimidazole riboside. Purity: ≥97% (TLC). Solubility: Soluble in DMSO (20mg/ml), 100% ethanol, and dimethyl formamide (100mM). Long Term Storage: -20°C.
Molecular Formula C12H12Cl2N2O4, Purity ≥98%, Formula Weight 319.1, Synonyms: 5,6-dichloro-1-β-D-ribofuranosyl-1H-benzimidazole, NSC 401575, Benzimidazole; Inhibits CKII (IC50 range of 4-10 M), Cdk7 (IC50 = ~20 M), Cdk8 (IC50 = ~20 M), and Cdk9 (IC50 = 3 M); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 M)
5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside | Mol Wt: 319.14 | 53-85-0 | MFCD00036785 | 10MG
Medchem Express / 56-Dichlorobenzimidazole riboside / 25mg / 705861044 / HY-14392 / / 53-85-0 / [null] / 319.140 / C12H12Cl2N2O4